Vor Biopharma
60 hedge funds and large institutions have $134M invested in Vor Biopharma in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more capital invested
Capital invested by funds: $128M → $134M (+$6.84M)
2% more funds holding
Funds holding: 59 → 60 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.05% less ownership
Funds ownership: 4.46% → 4.41% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$737K |
| 2 |
Morgan Stanley
New York
|
+$551K |
| 3 |
BlackRock
New York
|
+$298K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$94.5K |
| 5 |
Barclays
London,
United Kingdom
|
+$92.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.34M |
| 2 |
AG
Artal Group
Luxembourg
|
-$703K |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$317K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.5K |
| 5 |
Squarepoint
New York
|
-$33.3K |
VOR Hedge Fund Activity: Q4 2023 in Review
60 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2023, worth a combined $134M — up 5.4% from $128M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VOR positions and 5 closed out — a net gain of 2 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $737K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.34M sold.
- 60 institutional investors held Vor Biopharma (VOR) as of Q4 2023, up from 59 in Q3 2023.
- Funds reported $134M of Vor Biopharma stock for Q4 2023, up 5.4% quarter-over-quarter.
- 7 funds opened new Vor Biopharma positions in Q4 2023 and 5 closed out, a net change of +2 holders.
- The largest Vor Biopharma buyer in Q4 2023 was MAI Capital Management, an estimated $737K added.
- The largest Vor Biopharma seller in Q4 2023 was Baker Bros. Advisors, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2023.